Tacrolimus in Preventing Transplant Rejection in Chinese Patients--optimizing Use

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2015 Jan 23

PMID 25609922

Citations 14

Authors

Chuan-Jiang Li

Liang Li

Affiliations

Soon will be listed here.

Abstract

Tacrolimus is a product of fermentation of Streptomyces, and belongs to the family of calcineurin inhibitors. It is a widely used immunosuppressive drug for preventing solid-organ transplant rejection. Compared to cyclosporine, tacrolimus has greater immunosuppressive potency and a lower incidence of side effects. It has been accepted as first-line treatment after liver and kidney transplantation. Tacrolimus has specific features in Chinese transplant patients; its in vivo pharmacokinetics, treatment regimen, dose and administration, and adverse-effect profile are influenced by multiple factors, such as genetics and the spectrum of primary diseases in the Chinese population. We reviewed the clinical experience of tacrolimus use in Chinese liver- and kidney-transplant patients, including the pharmacology of tacrolimus, the immunosuppressive effects of tacrolimus versus cyclosporine, effects of different factors on tacrolimus metabolism on Chinese patients, personalized medicine, clinical safety profile, and patient satisfaction and adherence. This article provides guidance for the rational and efficient use of tacrolimus in Chinese organ-transplant patients.

Citing Articles

Tacrolimus induces insulin receptor substrate 1 hyperphosphorylation and inhibits mTORc1/S6K1 cascade in HL7702 cells.

Li H, Wang Y, Ran M, Gao F, Zhu B, Xiao H World J Diabetes. 2025; 16(2):97910.

PMID: 39959267 PMC: 11718479. DOI: 10.4239/wjd.v16.i2.97910.

Dynamic immune recovery process after liver transplantation revealed by single-cell multi-omics analysis.

Wang R, Peng X, Yuan Y, Shi B, Liu Y, Ni H Innovation (Camb). 2024; 5(3):100599.

PMID: 38510071 PMC: 10952083. DOI: 10.1016/j.xinn.2024.100599.

Incidental Finding of Post-Transplant Erythrocytosis After Renal Transplantation in a Patient With Chronic Kidney Disease: A Case Report.

Anthony N, Khan I, Shah A, Tariq A, Khan M Cureus. 2024; 15(12):e51218.

PMID: 38283474 PMC: 10821203. DOI: 10.7759/cureus.51218.

Suspicious of Acute Kidney Graft Rejection: Tacrolimus Pharmacokinetics Under Methylprednisolone Therapy.

Bidu N, Mattoso R, de Oliveira Santos O, Alves I, Fernandes B, Couto R Curr Drug Res Rev. 2023; 16(3):403-411.

PMID: 37861009 DOI: 10.2174/0125899775266172231004074317.

Population pharmacokinetic analyses of tacrolimus in non-transplant patients: a systematic review.

Wang C, Zhang Y, Zhao M, Zhao L Eur J Clin Pharmacol. 2023; 79(7):897-913.

PMID: 37261481 DOI: 10.1007/s00228-023-03503-6.

References

Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, OKUHARA M . FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987; 40(9):1249-55. DOI: 10.7164/antibiotics.40.1249. View

Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T . FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987; 40(9):1256-65. DOI: 10.7164/antibiotics.40.1256. View

Shu K, Ho H, Wen M, Wu M, Chen C, Cheng C . Changing pattern of mortality in renal transplant recipients: a single-center, 30-year experience. Transplant Proc. 2014; 46(2):442-4. DOI: 10.1016/j.transproceed.2013.11.032. View

Posadas Salas M, Srinivas T . Update on the clinical utility of once-daily tacrolimus in the management of transplantation. Drug Des Devel Ther. 2014; 8:1183-94. PMC: 4155987. DOI: 10.2147/DDDT.S55458. View

Jin J, Wu L, Wang W, Yu S, Yan S, Zheng S . Impact of multidrug resistance 1 gene polymorphism on tacrolimus dose and concentration-to-dose ratio in Chinese liver transplantation recipients. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2005; 22(6):616-20. View

Yu X, Xie H, Wei B, Zhang M, Wang W, Wu J . Association of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients. PLoS One. 2011; 6(11):e25933. PMC: 3215699. DOI: 10.1371/journal.pone.0025933. View

Staatz C, Taylor P, Tett S . Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant. 2001; 16(9):1905-9. DOI: 10.1093/ndt/16.9.1905. View

Wang Z, Song S, Teng F, Wang G, Guo W, Shi X . A single-center retrospective analysis of liver transplantation on 255 patients with hepatocellular carcinoma. Clin Transplant. 2009; 24(6):752-7. DOI: 10.1111/j.1399-0012.2009.01172.x. View

Wu P, Ni X, Wang M, Xu X, Luo G, Jiang Y . Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients. Ann Transplant. 2011; 16(1):54-60. View

10.

Butler J, Roderick P, Mullee M, Mason J, Peveler R . Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation. 2004; 77(5):769-76. DOI: 10.1097/01.tp.0000110408.83054.88. View

11.

Chen D, Fan J, Guo F, Qin S, Wang Z, Peng Z . Novel single nucleotide polymorphisms in interleukin 6 affect tacrolimus metabolism in liver transplant patients. PLoS One. 2013; 8(8):e73405. PMC: 3753270. DOI: 10.1371/journal.pone.0073405. View

12.

Huang H, Yao X, Chen Y, Xie W, Shen-Tu J, Chen J . Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. Int J Clin Pract Suppl. 2014; (181):4-9. DOI: 10.1111/ijcp.12400. View

13.

Ling Q, Xie H, Lu D, Wei X, Gao F, Zhou L . Association between donor and recipient TCF7L2 gene polymorphisms and the risk of new-onset diabetes mellitus after liver transplantation in a Han Chinese population. J Hepatol. 2012; 58(2):271-7. DOI: 10.1016/j.jhep.2012.09.025. View

14.

Zuo X, Ng C, Barrett J, Luo A, Zhang B, Deng C . Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genomics. 2013; 23(5):251-61. DOI: 10.1097/FPC.0b013e32835fcbb6. View

15.

Ji S, Li L, Sha G, Chen J, Liu Z . Conversion from cyclosporine to tacrolimus for chronic allograft nephropathy. Transplant Proc. 2007; 39(5):1402-5. DOI: 10.1016/j.transproceed.2006.11.030. View

16.

Zuo X, Zhou Y, Zhang B, Yang G, Cheng Z, Yuan H . Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine. Drug Metab Pharmacokinet. 2013; 28(5):398-405. DOI: 10.2133/dmpk.dmpk-12-rg-148. View

17.

Li L, Li C, Zheng L, Zhang Y, Jiang H, Si-Tu B . Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study. Eur J Clin Pharmacol. 2011; 67(8):787-95. DOI: 10.1007/s00228-011-1010-y. View

18.

Chen Y, Zheng K, Chen L, Dai Y, Fei J, Qiu J . Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. Transplant Proc. 2006; 37(10):4246-50. DOI: 10.1016/j.transproceed.2005.11.055. View

19.

Cheung C, Chan H, Liu Y, Chau K, Li C . Long-term graft function with tacrolimus and cyclosporine in renal transplantation: paired kidney analysis. Nephrology (Carlton). 2009; 14(8):758-63. DOI: 10.1111/j.1440-1797.2009.01155.x. View

20.

Zhang X, Wang Z, Fan J, Liu G, Peng Z . Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period. Eur J Clin Pharmacol. 2011; 67(8):803-13. DOI: 10.1007/s00228-011-0993-8. View